janus kinase (JAK) inhibitor - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.67 [0.52, 0.87]< 143%7 studies (7/-)99.9 %some concernserious moderatecrucial-
deaths 0.67 [0.52, 0.87]< 143%7 studies (7/-)99.9 %some concernserious moderatecrucial-
deaths (time to event analysis only) 0.59 [0.45, 0.78]< 10%2 studies (2/-)100.0 %lownot evaluable highcrucial-
clinical deterioration 0.78 [0.38, 1.60]< 156%2 studies (2/-)74.9 %lownot evaluable highimportant-
clinical improvement 1.22 [1.07, 1.39]> 110%5 studies (5/-)99.9 %some concernserious moderateimportant-
clinical improvement (14-day) 1.31 [1.13, 1.52]> 10%3 studies (3/-)100.0 %lownot evaluable highimportant-
clinical improvement (28-day) 1.92 [0.96, 3.82]> 10%3 studies (3/-)96.8 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.16 [1.01, 1.33]> 10%1 study (1/-)98.5 %lownot evaluable highimportant-
death or ventilation 0.78 [0.62, 0.99]< 156%3 studies (3/-)98.1 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.72 [0.49, 1.06]< 149%4 studies (4/-)95.0 %some concernnot evaluable moderateimportant-
recovery 1.57 [0.77, 3.20]> 10%1 study (1/-)89.3 %lownot evaluable highnon important-

safety endpoints 00

related AE (TRAE) 1.26 [0.14, 11.07]< 10%2 studies (2/-)41.9 %some concernnot evaluable moderateimportant-
superinfection 0.50 [0.32, 0.79]< 10%1 study (1/-)99.8 %lownot evaluable highimportant-
adverse events 0.12 [0.01, 1.37]< 12%2 studies (2/-)95.5 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.